Elanco (ELAN) executive logs new stock grants and tax withholding share disposal

Rhea-AI Filing Summary

Elanco Animal Health executive Jose Manuel Correia de Simas reported multiple equity compensation movements. He received an employee stock option grant for 23,220 shares at an exercise price of $0.0000 per share and 937 deferred stock units, both recorded as derivative awards.

He also acquired 21,507 and 11,364 shares of common stock as restricted stock unit grants, while 9,883 shares of common stock were disposed of at $26.40 per share to cover taxes, a tax-withholding disposition rather than an open-market sale. Footnotes state the option and stock unit grants vest in thirds on March 1, 2027, March 1, 2028, and March 1, 2029, with certain deferred units vesting on December 31, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Correia de Simas Jose Manuel

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		21,507	A	$0	102,907	D
Common Stock	03/01/2026		F		9,883	D	$26.4	93,024	D
Common Stock	03/01/2026		A		11,364(1)	A	$0	104,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$26.4	03/01/2026		A		23,220		(2)	03/01/2036	Common Stock	23,220	$0	23,220	D
Deferred Stock Units (Match)	(3)	03/01/2026		A		937		(4)	(4)	Common Stock	937	$0	937	D

Explanation of Responses:

1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

2. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

3. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

4. Deferred stock units vest December 31, 2027 and settle upon termination of employment or otherwise in accordance with the Executive Deferral and Stock Match Plan.

Remarks:

Executive Vice President, US Farm Animal Business

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jose Manuel Correia de Simas	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Elanco (ELAN) report for Jose Manuel Correia de Simas?

Jose Manuel Correia de Simas reported equity grants and a tax-related share disposition. He received stock options, deferred stock units, and restricted common shares, while 9,883 common shares were surrendered at $26.40 per share to satisfy tax withholding obligations under equity awards.

How many Elanco (ELAN) stock options and units were granted in this Form 4?

The executive received 23,220 stock options and 937 deferred stock units. These awards supplement grants of 21,507 and 11,364 shares of common stock, all characterized as grant or award acquisitions rather than open-market purchases, reflecting ongoing equity-based compensation for the reporting person.

Were any Elanco (ELAN) shares sold on the open market in this Form 4?

The filing reports a tax-withholding disposition, not an open-market sale. A total of 9,883 common shares were disposed of at $26.40 per share to cover tax liabilities associated with equity awards, consistent with transaction code F for payment of exercise price or tax obligations.

What are the vesting terms for the Elanco (ELAN) stock option and restricted unit grants?

The options and certain restricted stock units vest in three equal installments. Footnotes state one-third vests on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029, aligning with typical multi-year executive incentive structures.

How do the Elanco (ELAN) deferred stock units reported in the Form 4 work?

Each deferred stock unit equals one share of common stock or cash. Footnotes explain these units vest on December 31, 2027 and settle upon termination of employment or as specified in the Executive Deferral and Stock Match Plan, adding long-term, deferred compensation exposure.

Did the Elanco (ELAN) executive’s direct common stock holdings change after these transactions?

The Form 4 shows changes in directly held common stock balances. Following the reported grant and tax-withholding disposition transactions, the total directly owned common shares were updated in the filing, reflecting both new restricted stock awards and shares surrendered for tax purposes.